home / stock / ards / ards news


ARDS News and Press, Aridis Pharmaceuticals Inc. From 06/03/22

Stock Information

Company Name: Aridis Pharmaceuticals Inc.
Stock Symbol: ARDS
Market: NASDAQ
Website: aridispharma.com

Menu

ARDS ARDS Quote ARDS Short ARDS News ARDS Articles ARDS Message Board
Get ARDS Alerts

News, Short Squeeze, Breakout and More Instantly...

ARDS - Aridis Pharmaceuticals CEO to Participate in a Fireside Chat Presented by Maxim Group LLC and Hosted by M-Vest on June 7

Aridis Pharmaceuticals CEO to Participate in a Fireside Chat Presented by Maxim Group LLC and Hosted by M-Vest on June 7 PR Newswire LOS GATOS, Calif. , June 3, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company ...

ARDS - Aridis Pharmaceuticals GAAP EPS of -$0.44 beats by $0.07, revenue of $1.18M misses by $0.82M

Aridis Pharmaceuticals press release (NASDAQ:ARDS): Q1 GAAP EPS of -$0.44 beats by $0.07. Revenue of $1.18M misses by $0.82M. For further details see: Aridis Pharmaceuticals GAAP EPS of -$0.44 beats by $0.07, revenue of $1.18M misses by $0.82M

ARDS - Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update

Aridis Pharmaceuticals Announces First Quarter 2022 Financial Results and Business Update PR Newswire Multiple clinical data readouts expected in second half of 2022 LOS GATOS, Calif. , May 16, 2022 /PRNewswire/ -- Aridis Pharmaceuticals, Inc....

ARDS - Veru up 18% following late-breaking mid-stage data on sabizabulin for COVID-19

Veru (NASDAQ:VERU) shares are up 18% in Monday morning trading after the company presented phase 2 results over the weekend on oral sabizabulin in patients with severe COVID-19 at high risk for acute respiratory distress syndrome. In the trial of ~40 patients hospitalized with COVID...

ARDS - Aridis Pharmaceuticals GAAP EPS of -$0.92 misses by $0.59, revenue of $0.57M misses by $1.33M

Aridis Pharmaceuticals press release (NASDAQ:ARDS): Q4 GAAP EPS of -$0.92 misses by $0.59. Revenue of $0.57M misses by $1.33M. For further details see: Aridis Pharmaceuticals GAAP EPS of -$0.92 misses by $0.59, revenue of $0.57M misses by $1.33M

ARDS - Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update

Aridis Pharmaceuticals Announces 2021 Fourth Quarter and Year-End Financial Results and Business Update PR Newswire Awarded funding from the Gates Foundation to support development of inhaled formulation technology to deliver cost-effective monoclonal antibodies agai...

ARDS - Aridis, Rhythm top healthcare gainers; 10x Genomics, iSpecimen lead losers pack

Gainers: Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. Outset Medical (NASDAQ:OM) +10%. Masimo (NASDAQ:MASI) +8%. Vivos Therapeutics (NASDAQ:VVOS) +7%. Losers: 10x Genomics (NASDAQ:TXG) -16%. iSpecimen ISPC -10%. Poseida ...

ARDS - Aridis stock rises 6% as antibody cocktail AR-701 protects against Omicron in animal models

Pharmaceuticals (NASDAQ:ARDS) said both of its fully human monoclonal antibodies (mAbs) in the AR-701 cocktail neutralized the SARS-CoV-2 Omicron variant in in-vitro. In addition, both mAbs conferred complete protection against Omicron infected animals when given either parenterally or by int...

ARDS - Aridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals

Aridis' Pan-Coronavirus Monoclonal Antibody Cocktail AR-701 Is Protective in COVID-19 Omicron Infected Animals Preventative treatment of animals infected with the Omicron variant with either mAb alone or the combination of the two mAbs comprising the AR-701 cocktail conferred co...

ARDS - Short Squeeze Stocks: ARDS, BBIG and 3 Others Experts Think Are Ready to Pop

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today’s price action in the markets has been choppy. Investors seem to be having difficulty pricing in this macro environment, plus geopolitical concerns that are heating up. However, there are certain pockets of the...

Previous 10 Next 10